CLL Therapy Approaches in Russia

Plain-language summary

This observational study, sponsored by AstraZeneca, examines the treatment approaches used for patients with chronic lymphocytic leukemia (CLL/SLL) in Russia. It enrolled patients aged 18 and older diagnosed with CLL/SLL according to Russian clinical guidelines. This study has no assigned phase and is active but not currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

AstraZeneca

Start date

10/29/2021

Estimated completion

3/31/2027

Countries

Russia

Related genes

Locations

• Belgorod, Russia
• Bryansk, Russia
• Chelyabinsk, Russia
• Chita, Russia
• Irkutsk, Russia
• Kaliningrad, Russia
• Kaluga, Russia
• Kazan', Russia
• Kirov, Russia
• Krasnoyarsk, Russia
• Kurgan, Russia
• Mahachkala, Russia
• Moscow, Russia
• Nizhny Novgorod, Russia
• Novosibirsk, Russia
• Omsk, Russia
• Orenburg, Russia
• Perm, Russia
• Petropavlovsk-Kamchatskii, Russia
• Petrozavodsk, Russia
• Rostov-on-Don, Russia
• Saint-Petesburg, Russia
• Samara, Russia
• Saratov, Russia
• Syktyvkar, Russia
• Tver', Russia
• Ufa, Russia
• Ulan-Ude, Russia
• Vladimir, Russia
• Vladivostok, Russia
• Volgograd, Russia
• Vologda, Russia
• Yaroslavl, Russia
• Yekaterinburg, Russia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥18 years
* Ability and willing to sign the ICF
* Diagnosed CLL/SLL (including watch and wait stage of disease) according to Russian clinical guides

Exclusion Criteria:

* Patients without CLL/SLL diagnosis
* Age \<18 years
* Patients who refused/did not sign the ICF